Patients

Tessa is committed to improving the lives of cancer patients worldwide. Through the development of next-generation cell therapies, we seek to provide patients with more effective, safer and longer-lasting treatment options for a broad range of cancers.

T Cell Therapy Treatment: How Does it Work?

Allogeneic, Off-the-Shelf T Cell Therapy Treatment

Step 1: Blood Collection

Healthy donor’s blood is collected.

Step 2: Manufacturing

Donor’s white blood cells are isolated and T cells are engineered into T cell therapies.

Step 3: Harvest & Storage

CAR-T cells are harvested, cryo-preserved and stored in a secure cell bank before shipping.

Step 4: Shipment to Patients

Tessa ships the off-the-shelf CAR-T cell therapies to be administered to the patients.

Step 5: Infusion & Monitoring

CAR-T cells are intravenously infused into the patient and carefully monitored for any adverse reactions.

Actual therapy treatment for patients varies with cancer indications

Autologous T Cell Therapy Treatment

Step 1: Blood Collection

Patient’s blood is collected at hospital site.

Step 2: Transportation & Handling

Collected blood is transported to Tessa’s central production facility or satellite labs.

Step 3: Manufacturing

Patient’s white blood cells are isolated and T cells are engineered into T cell therapies.

Step 4: Shipment to Patients

Tessa ships the cell therapies to be administered to the patient.

Step 5: Infusion & Monitoring

Cell therapies are intravenously infused into the patient, who is carefully monitored for any adverse reactions.

Actual therapy treatment for patients varies with cancer indications

Target Indications

Our goal is to develop safe and effective cell therapies to transform the lives of patients with cancer. To learn more about available clinical trials, visit clinicaltrials.gov and search by company, disease or medicine.

Nasopharyngeal Cancer

Nasopharyngeal cancer (NPC) originates in the nasopharynx, an area at the upper part of the throat behind the nose. Approximately 92,5001 new cases of NPC are diagnosed worldwide each year with mortality of close to 55,0001. Although radiotherapy is the main avenue of treatment for early-stage NPC, 20-30% of patients are diagnosed at an advanced stage of disease and are not considered curable. NPC is strongly associated with Epstein-Barr Virus (EBV) infection, particularly in Asia, where close to 100% of NPC tumors are EBV-positive.

Cervical Cancer

Cervical cancer (CC) is a cancer that originates in the cervical tissue of the female reproductive tract. Approximately 560,0001 new cases of CC are diagnosed worldwide each year with mortality of close to 300,0001. Human papillomavirus (HPV) infection is frequently associated with CC and 70 – 80% of CC and may be HPV-positive. Surgery, chemotherapy and/or radiotherapy are often used to treat advanced CC.

Oropharyngeal Cancer

Oropharyngeal cancer (OPC) is a cancer that originates in the oropharynx, an area at the back of the mouth that connects to the esophagus. Approximately 154,0001 new cases of OPC are diagnosed worldwide each year with mortality of close to 100,0001. 70% of these cancers are HPV-positive. Chemotherapy/Radiotherapy and/or surgery may be used to treat OPC. As with CC, vaccines against HPV are unable to treat OPC patients who are already infected with the virus.

Epstein-Barr Virus (EBV)-associated lymphomas

Malignant lymphomas are malignancies arising from lymphoid organs and tissues. Approximately 589,580 new cases of lymphoma were diagnosed worldwide with mortality of 274,891 in 20181. Oncogenic EBV is associated with various types of lymphoma, including post-transplant lymphoproliferative disease (PTLD),  Hodgkin lymphoma (HL), Non-Hodgkin lymphoma (NHL) and NK/T cell lymphoma2. Standard treatments of advanced HL and NHL are chemotherapy, radiotherapy and targeted therapy, and recently, CAR-T cell therapy was approved for a type of NHL. PTLD currently has limited treatment options with anti-CD20 antibody as the standard treatment.

1. Globocan 2018, http://gco.iarc.fr/
2. Malignancies associated with epstein-barr virus: pathobiology, clinical features, and evolving treatments. Neparidze N, Lacy J,  Clin Adv Hematol Oncol. 2014 Jun;12(6):358-71.

CD30-positive Hodgkin lymphoma

CD30 is universally expressed in classical Hodgkin Lymphoma (cHL). Patients with relapsed or refractory cHL have limited treatment options and poor outcomes despite recently approved immune-checkpoint inhibitors indicated for patients who have relapsed after 3 or more lines of therapy.

Expanded Access

Tessa Therapeutics is dedicated to the development of next-generation cell therapies for a variety of hematologic malignancies and solid tumors.

At this stage of our drug development program for investigational product CD30-directed genetically modified autologous T cells (CD30.CAR-T), we are evaluating the safety and efficacy of our proprietary process of isolating human T cells from peripheral blood mononuclear cells for infusion into patients with resistant Hodgkin lymphoma. This research is being conducted through clinical trials that—with continued success—may provide the basis for a submission to the U.S. Food and Drug Administration (FDA) for drug approval.

To learn more about our clinical trials, including eligibility requirements for participating in ongoing studies, please visit ClinicalTrials.gov, a U.S. government-run database listing private and publicly funded clinical studies conducted around the world.

As part of the drug development process, the FDA allows for Expanded Access or Compassionate Use of investigational drugs prior to regulatory approval.  At this time, Tessa Therapeutics does not have a compassionate use program. As cell therapy is a specialized process, we prefer that Hodgkin lymphoma patients consult with a nearest clinical site—since these physicians and facilities are most able to deliver the complex treatment and monitoring required.

For any additional questions, please contact us at clinicaltrials@tessatherapeutics.com